Koronis Pharma
Biotechnology ResearchWashington, United States2-10 Employees
Koronis Pharma, Inc. is a biotechnology company developing a novel class of antiviral therapeutics centered on Viral Decay Acceleration, a mechanism intended to accelerate the decay of viruses by increasing their mutation rate. The lead candidate, KP-1461, targets HIV, with additional products in development for hepatitis C, reflecting a focus on treatments where resistance to existing therapies presents ongoing challenges. Based in Seattle, Washington, the company operates in a field that seeks to address unmet needs in viral infections by offering a distinct therapeutic approach rather than conventional enzyme inhibition. The organization is small in scale, with a focus on advancing antiviral programs through research and development alongside its niche market of infectious disease treatment, where innovative strategies are pursued to manage conditions such as HIV and hepatitis C. A recent development noted is the progression of KP-1461 as the lead candidate for HIV treatment, signaling ongoing activity in its pipeline.
1-888-653-2347 
support@leadiq.com 
